Founded in 2015, Edesa Biotech brings innovative new treatments for dermatological and anorectal diseases. Late-stage prescription drugs developed by Edesa Biotech aim to help patients who experience limited treatment options. Edesa Biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
Location: Canada, Ontario, Markham
Employees: 11-50
Total raised: $32.12M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.10.2023 | - | $16.81M | - |
| 02.02.2021 | - | $10.95M | - |
| 06.01.2020 | - | $4.36M | - |
Mentions in press and media 23
| Date | Title | Description |
| 12.10.2023 | Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government | Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical s... |
| 10.02.2023 | Edesa Biotech Reports Fiscal 1st Quarter 2023 Results | TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31... |
| 10.02.2023 | Edesa Biotech Reports Fiscal 1st Quarter 2023 Results | TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended De... |
| 16.12.2022 | Edesa Biotech Reports Fiscal Year 2022 Results | TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended Sep... |
| 12.08.2022 | Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results | Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage ... |
| 11.07.2022 | Edesa Biotech to Present at ARDS Drug Development Summit | TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, wi... |
| 19.05.2022 | Edesa Biotech to Present at H.C. Wainwright Global Investment Conference | TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, wil... |
| 13.05.2022 | Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results | TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended... |
| 28.04.2022 | Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected | Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drug TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinica... |
| 24.03.2022 | Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering | TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registere... |
Show more